Coronary Artery Disease

Coronary artery disease (CAD) is a chronic condition in which plaque accumulation narrows or obstructs the coronary arteries, limiting blood flow to the heart muscle. It is closely associated with atherosclerosis and can lead to angina, myocardial infarction, heart failure, arrhythmias, and premature death. Major modifiable risk factors include hypertension, dyslipidemia, diabetes, tobacco use, obesity, unhealthy diet, physical inactivity, and excess alcohol consumption. Age, family history, sex, and inherited conditions also influence risk. Effective management combines prevention, timely diagnosis, lifestyle intervention, medicines, and-when clinically appropriate-revascularization.

CAD care is shifting from episodic treatment toward integrated prevention and long-term risk management. Earlier identification of elevated blood pressure, abnormal lipids, diabetes, kidney disease, and familial risk is supporting more individualized prevention strategies. Diagnostic pathways increasingly combine clinical assessment with electrocardiography, laboratory testing, noninvasive imaging, and, when indicated, invasive coronary angiography. Care delivery is also becoming more coordinated across primary care, emergency services, cardiology, rehabilitation, and community settings, while remote monitoring and digital follow-up can help support adherence and earlier escalation of care.

Artificial intelligence is being applied to cardiovascular imaging, electrocardiogram interpretation, risk prediction, clinical decision support, and operational triage. Its potential value includes identifying subtle imaging or signal patterns, prioritizing patients for review, reducing diagnostic delays, and supporting personalized prevention. However, clinical usefulness depends on representative training data, external validation, transparent performance reporting, cybersecurity, interoperability, and clinician oversight. AI should augment-not replace-professional judgment, particularly where symptoms, comorbidities, and treatment risks require contextual interpretation.

North America has substantial capacity for advanced diagnostics, preventive medicines, intervention, and cardiac rehabilitation, but disparities in affordability, adherence, and access remain important. Latin America faces a combination of urbanization, metabolic risk, tobacco exposure, and uneven availability of specialist and emergency services. Europe benefits from established cardiovascular guidelines and health systems, while aging populations and unequal access across countries continue to shape outcomes. The Middle East is managing rising cardiometabolic risk alongside rapid health-system development. Africa faces a dual burden of limited access to acute cardiac care and growing hypertension, diabetes, and urban lifestyle risks. Asia-Pacific is highly diverse: several economies have advanced cardiac infrastructure, while others continue to address late diagnosis, rural access gaps, and rapid changes in diet and physical activity.

ASEAN countries share challenges involving urbanization, affordability, workforce distribution, and variable access to diagnostics and emergency cardiac services, making regional primary-care strengthening valuable. BRICS members face wide internal and cross-country differences in prevention, data systems, specialist capacity, and access to medicines and procedures. The European Union can benefit from coordinated prevention policies, interoperable health information, and consistent quality measurement while respecting national health-system structures. G7 countries generally possess strong research and clinical capabilities, but aging, multimorbidity, health inequities, and pressure on healthcare workforces remain central concerns. GCC countries are addressing high cardiometabolic risk through prevention, screening, and modernization of care pathways. NATO members may benefit from shared preparedness, clinical training, and continuity planning for cardiovascular services during emergencies.

Australia emphasizes guideline-based prevention, rural and Indigenous health equity, and access to specialist care across dispersed communities. Brazil must combine primary-care prevention with improved access to timely diagnosis and acute coronary treatment. Canada faces geographic access challenges alongside the need to reduce inequities affecting Indigenous and remote populations. China is expanding chronic-disease management while addressing hypertension, diabetes, aging, and urban-rural differences. France, Germany, Italy, Spain, and the United Kingdom have established cardiology services but must manage aging, multimorbidity, prevention gaps, and pressure on healthcare capacity. India’s priorities include earlier detection, affordable medicines, workforce expansion, and stronger emergency pathways across urban and rural settings. Japan is focused on aging-related disease management, prevention, and sustained rehabilitation. Mexico needs stronger risk-factor control, primary-care continuity, and timely access to acute services. Russia faces significant prevention and treatment challenges related to risk-factor burden, regional variation, and continuity of care. South Korea combines advanced healthcare capabilities with priorities involving aging, metabolic risk, prevention, and equitable access.

Industry leaders should strengthen risk-factor detection through primary care, pharmacies, workplaces, and community programs, with culturally appropriate support for adherence and lifestyle change. Care pathways should define rapid escalation for suspected acute coronary syndromes, connect emergency and specialist services, and expand cardiac rehabilitation after diagnosis or intervention. Organizations should invest in interoperable records, validated remote monitoring, and workforce training while measuring outcomes across underserved populations. AI initiatives should begin with clearly defined clinical use cases, prospective validation, bias monitoring, explainability, privacy safeguards, and accountable human review. Partnerships with public-health agencies, payers, clinicians, patients, and community organizations can improve implementation and trust.

This executive summary synthesizes established clinical and public-health evidence on coronary artery disease, including recognized risk factors, prevention principles, diagnostic pathways, treatment approaches, health-system constraints, and emerging applications of artificial intelligence. Regional, group, and country observations are framed as qualitative comparisons of epidemiology, healthcare capacity, access, policy context, and implementation needs. Claims should be corroborated against current national guidelines, peer-reviewed research, public-health surveillance, regulatory documentation, and local clinical data before operational or investment decisions are made. No market estimates, market sizing, market shares, or forecasts are used.

CAD outcomes depend on how effectively health systems prevent risk, recognize symptoms, deliver timely treatment, and sustain secondary prevention over the long term. The central opportunity is to connect population-level prevention with accessible, evidence-based clinical care, supported by reliable data and carefully governed digital tools. Regional and national differences require tailored implementation rather than a single model. Leaders that prioritize equity, measurable quality, clinical validation, and coordinated care will be better positioned to reduce avoidable cardiovascular harm.